Introduction {#Sec1}
============

The enteric-coated formulation of mycophenolate sodium (EC-MPS, Myfortic^®^, Novartis Pharma AG, Basel, Switzerland), used in the prophylaxis of organ rejection, was developed to reduce the incidence of adverse gastrointestinal effects of its active compound, mycophenolic acid (MPA) (Budde et al. [@CR5]; Sánchez Fructuoso et al. [@CR24]). EC-MPS has similar safety profile and adverse gastrointestinal effects incidence (Salvadori et al. [@CR23]; Budde et al. [@CR4]) to mycophenolate mofetil (MMF, CellCept^®^, Roche AG, Basel, Switzerland). EC-MPS is still most often administrated basing on fixed doses, without monitoring MPA concentrations although MPA is characterized by high protein binding (97--99 %) (Chen et al. [@CR7]) as well as high intra- and interpatient variability of its pharmacokinetics and pharmacodynamics (Budde et al. [@CR5]; Sánchez Fructuoso et al. [@CR24]). The EC-MPS therapy is most often controlled only by assessing patient's clinical condition, although there are some data indicating the efficacy-exposure relationship. In some studies, the correlation between small drug concentration and the risk of acute rejection or between high drug concentration and adverse effects intensity (Budde et al. [@CR4], [@CR5]; Sánchez Fructuoso et al. [@CR24]; Durlik and Rowiński [@CR10]) was observed. The best method for effective and safe immunosuppressive therapy is monitoring the active metabolite plasma concentration (Durlik and Rowiński [@CR10]), especially as MPA pharmacokinetics may be influenced by co-administration of other immunosuppressant agents, albumin concentration and renal function as well as the pharmacokinetics may vary depending on the type of organ transplanted (Budde et al. [@CR5]).

Pharmacokinetic parameters of MPA and its inactive metabolite, MPA glucuronide (MPAG), depend on the kind of calcineurin inhibitor \[cyclosporine (CsA) or tacrolimus (Tac)\] co-administrated. CsA may affect the enterohepatic recirculation of MPAG, leading to MPA AUC decrease, whereas Tac influence on the recirculation is probably lower; therefore, MPA exposure is higher in EC-MPS and Tac-treated patients (Kaplan et al. [@CR16]). According to our knowledge, the influence of CsA on EC-MPS pharmacokinetics is widely described in the literature (Budde et al. [@CR4]; Sanford and Keating [@CR25]; Budde et al. [@CR5]; Capone et al. [@CR6]; Stracke et al. [@CR27]). Although EC-MPS is also frequently co-administered with Tac, more data need to be evaluated for safe and effective therapy (Budde et al. [@CR3]; Sánchez Fructuoso et al. [@CR24]; Ju et al. [@CR15]; Lee et al. [@CR18]; Li et al. [@CR20]).

The main difficulty is that the determination of the area under the plasma concentration--time curve from 0 to 12 h (AUC~0--12~), which describes best MPA total body exposure, is inconvenient, expensive and difficult to achieve as well as influenced by MPA enterohepatic recirculation. Therefore, there are attempts to determine *C*~0~ in clinical practice, although poor correlation between MPA *C*~0~ and AUC~0--12~ is observed (Budde et al. [@CR4]; Durlik and Rowiński [@CR10]).

The aim of the study was to investigate the pharmacokinetics of EC-MPS metabolites (MPA, fMPA and MPAG) and the clinical condition of kidney transplant recipients receiving concomitantly Tac and steroids in the first year after transplantation.

Patients and methods {#Sec2}
====================

Patients {#Sec3}
--------

The study included 18 patients aged 34--72 years within 1 year after transplantation (14--307 days), receiving EC-MPS orally at a daily dose of 1,440 mg (720 mg bid) in combination with Tac and steroids (prednisolone). The inclusion criteria were Tac treatment (Advagraf or Prograf) and appropriate EC-MPS dosage (the same dose twice a day). The exclusion criteria were CsA treatment, EC-MPS given in different dosage schedule than twice a day or at two different doses. The patients' demographics and clinical characteristics are presented in Table [1](#Tab1){ref-type="table"}. The protocol biopsies were not performed. Biopsies were taken in the case of acute rejection suspicion based on clinical symptoms. After receiving the biopsy result (within 24 h) definitive diagnosis was made. None of the patients showed biopsy-proven acute rejection.Table 1Demographic and clinical data of 18 renal transplant recipientsParameterMedianMin--MaxGenderMale: 10; female: 8Age (years)5534--72Post-transplant period (days)3414--307Tacrolimus dose (mg/day)75--16Creatinine concentration (mg/dL)2.11.1--7.3Creatinine clearance (mL/min/1.73 m^2^)31.97.3--83.5Platelets count (10^−9^/L)20967--380White blood cells count (10^−9^/L)7.93.2--17.3Hemoglobin concentration (g/dL)11.29.1--16.7Alanine aminotransferase (U/L)307--177Aspartate aminotransferase (U/L)199--43

The study was approved by the Bioethical Committee at Poznan University of Medical Sciences and is in accordance with the Helsinki Declaration of 1975. Informed consent was obtained from the patients prior to initiating the study.

MPA, fMPA and MPAG determination {#Sec4}
--------------------------------

Blood samples were collected into EDTA tubes before the morning dose of EC-MPS (*C*~0~), and subsequently at 30 min (*C*~0.5~), 1 h (*C*~1~), 2 h (*C*~2~), 3 h (*C*~3~), 4 h (*C*~4~), 6 h (*C*~6~), 9 h (*C*~9~) and 12 h (*C*~12~) after EC-MPS administration. All patients were at the steady state on the day of blood collection.

MPA and MPAG plasma concentrations were determined using the validated HPLC method described elsewhere (Elbarbry and Shoker [@CR11]; Chrzanowska et al. [@CR8]) with minor modification. 200 μL of plasma was mixed with 100 μL of MPA and MPAG standard solutions for the calibration curve or substituted for 100 μL of methanol in the case of patients' plasma samples. Subsequently, 200 μL of phenytoin (internal standard) dissolved in 0.1 mol/L orthophosphoric acid in acetonitrile was added.

Free MPA (fMPA) was analyzed according to the method described elsewhere (Chen et al. [@CR7]) in all plasma samples. The analytical column used for fMPA determination was Zorbax Eclipse XDB C18 (150 mm × 4.6 mm, 5 µm, Agilent Inc., USA).

Pharmacokinetic calculations {#Sec5}
----------------------------

The following pharmacokinetic parameters for MPA, fMPA and MPAG were calculated: *C*~0~, *C*~max~, *t*~max~ and AUC from 0 to 4 h (AUC~0--4~) and from 0 to 12 h (AUC~0--12~) using the linear trapezoidal rule. The creatinine clearance (CL~cr~) was estimated using Chronic Kidney Disease Epidemiology Collaboration equation (Levey et al. [@CR19]). For fMPA, the fraction of fMPA (%) was also calculated.

Statistical analysis {#Sec6}
--------------------

All statistical tests were performed using Statistica software version 10.0 (StatSoft, Cracow, Poland). Normality was determined by the Shapiro--Wilk test. The correlations of data were tested using Pearson or Spearman correlation analysis for the normally and non-normally distributed data, respectively. A *p* value lower than 0.05 was considered significant. The results are presented as mean ± standard deviation (SD). Coefficient of variation (CV) was used to express variability of pharmacokinetic parameters.

Results {#Sec7}
=======

Pharmacokinetic parameters of MPA, fMPA and MPAG {#Sec8}
------------------------------------------------

Individual plasma concentrations of MPA, fMPA and MPAG versus time for all patients included in the study are shown on Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Individual plasma concentrations of mycophenolic acid (MPA; **a**), free MPA (fMPA; **b**) and mycophenolate glucuronide (MPAG; **c**) versus time in 18 kidney transplant recipients treated with enteric-coated mycophenolate sodium (EC-MPS) and tacrolimus (Tac)

The calculated MPA, fMPA and MPAG pharmacokinetic parameters are presented in Table [2](#Tab2){ref-type="table"}. Plasma concentrations of MPA, fMPA and MPAG as well as the pharmacokinetic parameters of EC-MPS metabolites were highly variable. Median MPA *C*~0~ was 3.1 μg/mL and the highest MPA *C*~0~ in our study was 10.6 μg/mL. 50 % of patients reached MPA AUC~0--12~ therapeutic range of 30--60 µg h/mL, whereas for the rest of the patients MPA AUC~0--12~ was \>60 µg h/mL. For 33 % MPA AUC~0--12~ value was within 40--60 µg h/mL.Table 2The pharmacokinetic parameters of MPA, fMPA and MPAG in renal transplant recipientsParameterMPAfMPAMPAGMean ± SDMedianCV (%)Mean ± SDMedianCV (%)Mean ± SDMedianCV (%)*C* ~0~ (µg/mL)4.2 ± 3.03.171.60.030 ± 0.0250.02283.4117.3 ± 78.296.966.7*C* ~max~ (µg/mL)18.1 ± 7.516.141.30.174 ± 0.1070.15661.3163.8 ± 76.8148.146.9*t* ~max~ (h)2.0 ± 0.62.029.72.0 ± 1.02.051.43.4 ± 1.63.048.7AUC~0--12~ (µg h/mL)67.4 ± 30.661.445.40.487 ± 0.2940.44960.31,547.5 ± 844.71,393.254.6AUC~0--4~ (µg h/mL)34.2 ± 14.328.241.80.450 ± 0.2850.41063.4577.2 ± 417.7472.672.4fMPA fraction (%)------0.90 ± 0.760.7784.1------

The average percentage of fMPA fraction was 0.90 ± 0.76 % (median 0.77 %, range 0.28--7.29 %). The median fMPA AUC~0--12~ was 0.449 µg h/mL. In 11 of 18 patients (61 %) fMPA AUC~0--12~ was \>0.4 µg h/mL.

Most of the MPA, fMPA and all MPAG concentrations correlated significantly with MPA, fMPA and MPAG AUC~0--12~ and AUC~0--4~ as presented in Table [3](#Tab3){ref-type="table"}. MPA *C*~2~ did not correlate with MPA AUC~0--12~. Moreover, MPA *C*~0~ and *C*~0.5~ did not correlate with MPA AUC~0--4~.Table 3Correlations between MPA, fMPA and MPAG concentrations and respective AUC~0--4~ and AUC~0--12~ in renal transplant recipients*C* (µg/mL)MPAfMPAMPAGAUC~0--12~ (µg h/mL)AUC~0--4~ (µg h/mL)AUC~0--12~ (µg h/mL)AUC~0--4~ (µg h/mL)AUC~0--12~ (µg h/mL)AUC~0--4~ (µg h/mL)*rprprprprprpC* ~0~0.5600.0160.4040.0970.7320.0010.752\<0.0010.955\<0.0010.950\<0.001*C* ~0.5~0.5640.0150.4430.0660.7090.0010.7280.0010.955\<0.0010.955\<0.001*C* ~1~0.5950.0090.6180.0060.804\<0.0010.796\<0.0010.971\<0.0010.977\<0.001*C* ~2~0.3350.1740.5500.0180.5250.0250.5110.0300.833\<0.0010.884\<0.001*C* ~3~0.858\<0.0010.769\<0.0010.5030.0340.4960.0360.942\<0.0010.957\<0.001*C* ~4~0.759\<0.0010.5890.0100.4570.0560.4370.0700.975\<0.0010.953\<0.001*C* ~6~0.6660.003----0.3130.206----0.948\<0.001----*C* ~9~0.6390.004----0.847\<0.001----0.959\<0.001----*C* ~12~0.6660.003----0.6120.007----0.948\<0.001----*C* ~max~0.5170.0280.781\<0.0010.872\<0.0010.874\<0.0010.959\<0.0010.953\<0.001

The median MPAG AUC~0--12~ was about 20-fold higher than MPA AUC~0--12~ values.

In our study, there were no differences in MPA, fMPA and MPAG pharmacokinetic parameters between patients \<30 days after the transplantation and patients \>30 days after the transplantation (data not shown).

Kidney function {#Sec9}
---------------

The influence of kidney function on pharmacokinetic parameters was analyzed regarding creatinine clearance (CL~cr~) and creatinine concentration (*C*~cr~). MPAG pharmacokinetic parameters (AUC~0--4~, AUC~0--12~, *C*~0~, *C*~max~) correlated negatively with CL~cr~ and positively with *C*~cr~, whereas none of the MPA pharmacokinetic parameters correlated with CL~cr~ and *C*~cr~. AUC~0--12~ of fMPA correlated positively with *C*~cr~ (Table [4](#Tab4){ref-type="table"}).Table 4Correlations between MPA, fMPA and MPAG pharmacokinetic parameters and renal function in renal transplant recipientsMPAfMPAMPAG*rprprp*Creatinine clearance (mL/min) AUC~0--4~ (µg h/mL)−0.0240.926−0.3730.128−0.6900.002 AUC~0--12~ (µg h/mL)0.0630.804−0.4140.088−0.6570.003 *C* ~0~ (µg/mL)−0.1910.448−0.3560.147−0.6970.001 *C* ~max~ (µg/mL)0.168\*0.505−0.207\*0.409−0.630\*0.005Creatinine concentration (mg/dL) AUC~0--4~ (µg h/mL)0.0460.8550.4670.0510.6760.002 AUC~0--12~ (µg h/mL)−0.0130.9580.4940.0370.6340.005 *C* ~0~ (µg/mL)0.2760.2680.4360.0710.6540.003 *C* ~max~ (µg/mL)−0.0310.9030.3720.1290.6050.008\* Pearson correlation analysis

Patient characteristics and complete blood count parameters {#Sec10}
-----------------------------------------------------------

None of the MPA, fMPA and MPAG pharmacokinetic parameters correlated either with patient characteristics (age, weight, post-transplant period and Tac dose; data not shown) or with the results of the complete blood count tests \[white blood cell (WBC) and platelet (PLT) count, hemoglobin (Hb) concentration; data not shown\] with the exceptions of the negative correlations between Hb concentration and MPA *C*~0~ (*r* = −0.475; *p* = 0.046) as well as fMPA C~0~ (*r* = −0.540, *p* = 0.021).

Discussion {#Sec11}
==========

The aim of our study was to calculate the pharmacokinetic parameters of MPA, fMPA and MPAG in renal transplant recipients treated with EC-MPS, Tac and steroids within 1 year after the transplantation and to compare the results with the literature data concerning EC-MPS administration with either CsA or Tac. We also assessed the influence of kidney function as well as other clinical factors on EC-MPS metabolites pharmacokinetics. Additionally, MPA and MPAG concentrations were correlated with MPA and MPAG AUC~0--12~ as well as with the abbreviated AUC~0--4~. The results may contribute to assess limited sampling strategy (LSS), which would be more convenient for patients and may be useful for individualizing drug dosage (Pawinski et al. [@CR22]).

Consistent with the literature data (Budde et al. [@CR4]; Hummel et al. [@CR14]; Shah et al. [@CR26]; Fleming et al. [@CR12]), plasma concentrations of MPA, fMPA and MPAG in our study were found to range widely. According to the CV values, the pharmacokinetic parameters of EC-MPS metabolites were highly variable as well.

Our results are in accordance with the literature data concerning the influence of calcineurin inhibitors on MPA and MPAG pharmacokinetics. In patients included in our study, MPA pharmacokinetic parameters were higher in comparison to patients receiving EC-MPS in combination with CsA (Budde et al. [@CR4]; Stracke et al. [@CR27]) and comparable to the literature data in Chinese patients receiving EC-MPS and Tac with the exception of shorter MPA *t*~max~ in our study (5.0 vs. 2.0 h) (Li et al. [@CR20]). MPA *t*~max~ in our study was comparable, however, to most of the literature data (1.5--3.5 h) (Budde et al. [@CR3]; Shah et al. [@CR26]; Tett et al. [@CR29]; Stracke et al. [@CR27]). All MPAG pharmacokinetic parameters in our study were lower than those in patients receiving EC-MPS with CsA (Stracke et al. [@CR27]). The median MPAG AUC~0--12~ was about 20-fold higher than MPA AUC~0--12~ values and the result was lower than those in patients receiving EC-MPS in combination with CsA (52-fold higher for MPAG) (Stracke et al. [@CR27]).

The target recommended MPA *C*~0~ value is ≥1.3 and ≥1.9 μg/mL for renal transplant recipients receiving MMF with CsA and MMF with Tac, respectively (van Gelder et al. [@CR30]). Although it has not been thoroughly investigated, the target MPA *C*~0~ for MMF may not be applicable for EC-MPS due to two reasons. First, the enteric-coating of EC-MPS delays the occurrence of *C*~max~ and second, after EC-MPS administration higher and more variable MPA *C*~0~ with overall MPA exposure similar to that observed after MMF administration are observed (Budde et al. [@CR3], [@CR4]; Stracke et al. [@CR27]). For MMF and Tac, MPA *C*~0~ \>3 µg/mL may be related to more common adverse effects (Borrows et al. [@CR2]); however, in our study, 9 of 18 patients (50 %) had MPA *C*~0~ \>3 µg/mL and no significant adverse effects were observed. None of the patients in our study reached MPA *C*~0~ 15 μg/mL, which could be related to very prolonged release of MPA from the evening EC-MPS dose. It is proved that MPA and MPAG exposures increased from week 2 to week 12 post-transplant after prolonged EC-MPS and CsA co-administration (Hummel et al. [@CR14]). In our study, however, probably due to a small number of patients, none of the MPA or MPAG pharmacokinetic parameters correlated with the post-transplant period and we did not observe any differences in the pharmacokinetics between patients who were within 30 days \[the early post-transplant period (Stracke et al. [@CR27])\], and those who were more than 30 days after the transplantation. The highest and the lowest MPAG *C*~0~ were observed 22 and 14 days after the transplantation, respectively. The only patient who was \>6 months after the transplantation had one of the lowest MPA and MPAG *C*~0~ values.

The target MPA AUC value, recommended for sufficient immunosuppression in renal transplant recipients receiving MMF and CsA, especially in the early post-transplant period, is 30--60 μg h/mL (van Gelder et al. [@CR30]; Sanford and Keating [@CR25]) or 40--60 μg h/mL for EC-MPS and CsA therapy (Glander et al. [@CR13]; Stracke et al. [@CR27]). MPA AUC~0--12~ therapeutic range of 30--60 µg h/mL was reached in 9 of 18 patients (50 %) included in our study. The AUC~0--12~ values in the remaining 50 % of the patients exceeded the upper limit of the therapeutic range (\>60 µg h/mL). Although the toxic range for MPA AUC has not been established, AUC \>60 µg h/mL may be related to the increased incidence of the adverse events such as leucopenia, thrombocytopenia and gastrointestinal disorders. Some authors also observed high MPA AUC~0--12~ after EC-MPS and Tac therapy without greater incidence of the adverse effects (Shah et al. [@CR26]; Sánchez Fructuoso et al. [@CR24]). Sumethkul et al. ([@CR28]) reported high MPA AUC exposure (\>60 µg h/mL) also after EC-MPS and CsA therapy. The percentage of patients (33 %), who reached MPA AUC~0--12~ therapeutic range of 40--60 µg h/mL in our study, was slightly higher than in the Stracke et al. (25 %) study. Apart from the kind of calcineurin inhibitor administered, higher MPA AUC may be due to a different MPA determination method (enzyme-multiplied immunoassay) (Sánchez Fructuoso et al. [@CR24]).

The data concerning the relationship between MPA exposure and the incidence of acute rejection are limited in renal transplant recipients treated with EC-MPS (Le Meur et al. [@CR17]). According to the literature (Budde et al. [@CR5]), patients with biopsy-proven acute rejection showed lower MPA AUC~0--12~ (28 µg h/mL) in comparison to the rejection-free patients (MPA AUC~0--12~ 40 µg h/mL). In our study, we did not observe any acute rejection, probably because MPA AUC~0--12~ was \>30 µg h/mL in all patients.

In our study, MPA *C*~0~ correlation with AUC~0--12~ was weaker than that in the Budde et al. ([@CR4]) study and stronger than that in the Stracke et al. ([@CR27]) study. Poor correlations between *C*~0~ and total MPA AUC, which may be even weaker for EC-MPS than for MMF, indicate that MPA *C*~0~ does not reflect systemic exposure to MPA regardless of the kind of calcineurin inhibitor (CsA or Tac) co-administered (Pawinski et al. [@CR22]; Budde et al. [@CR4]; Neumann et al. [@CR21]; de Winter et al. [@CR9]; Sánchez Fructuoso et al. [@CR24]; Li et al. [@CR20]). In our study, all MPA concentrations (except for *C*~2~) correlated significantly with MPA AUC~0--12~ as well as with MPA AUC~0--4~. The most significant correlations were observed for MPA *C*~3~ and *C*~4~ similar to or even stronger than those in the literature (Sánchez Fructuoso et al. [@CR24]; Stracke et al. [@CR27]). However, in the case of EC-MPS some authors suggest that the estimation of MPA AUC~0--12~ based on the plasma concentrations drawn within 2 or 3 h after dosing is likely to provide conflicting results due to the variability in MPA *t*~max~ (Tett et al. [@CR29]). In patients included in our study, MPA *C*~12~ correlated significantly with AUC~0--12~ stronger than in the Stracke et al. ([@CR27]) study, whereas in Chinese patients treated with EC-MPS and Tac, MPA *C*~7~ predicted MPA AUC the best (Li et al. [@CR20]).

In therapeutic monitoring, MPA *C*~max~ should preferably rather not be used due to its weaker correlation with MPA AUC~0--12~ and great *t*~max~ variability (Budde et al. [@CR3]; Shah et al. [@CR26]; Tett et al. [@CR29]; Stracke et al. [@CR27]). This is confirmed in our study as the correlation between MPA *C*~max~ and MPA AUC~0--12~ was the second weakest.

All MPAG concentrations correlated significantly with MPAG AUC~0--12~ and AUC~0--4~. The best correlations were seen between *C*~1~ and *C*~4~ and the weakest in *C*~2~. According to the literature data, patients treated with EC-MPS in combination with CsA, *C*~0~, *C*~2~, *C*~12~ and *C*~max~ correlated well with the MPAG AUC~0--12~ (Stracke et al. [@CR27]).

Additionally, we observed significant correlations between most of the fMPA concentrations and fMPA AUC~0--12~ and AUC~0--4~. This finding may contribute to therapeutic monitoring as the determination method of fMPA is fast and easy (Chen et al. [@CR7]). Median fMPA AUC~0--12~ presented in our study was similar to the literature data (0.48 µg h/mL) but median fMPA fraction was lower (0.77 vs. 1.65 %) (Stracke et al. [@CR27]).

Higher values of MPAG pharmacokinetic parameters observed in patients with lower CL~cr~ and higher *C*~cr~ are in accordance with the literature data. Some authors observed significant negative correlations between glomerular filtration rate and MPAG and fMPA AUC~0--12~ and lack of correlation for MPA AUC~0--12~ (Stracke et al. [@CR27]). According to the literature data, high values of MPAG pharmacokinetic parameters result from MPAG accumulation in patients with impaired renal function (Behrend and Braun [@CR1]). We also observed higher fMPA *C*~0~ in patients with lower CL~cr~. Our results showed that in one patient with very high MPA and MPAG concentrations, *C*~cr~ amounted to 7.3 mg/dL and exceeded the reference range by about fivefold. The CL~cr~ value for this patient (7.3 mL/min 1.73 m^2^) indicated end-stage renal insufficiency.

We also analyzed the influence of complete blood count parameters, such as WBC and PLT counts, Hb concentration, as well as other factors (patients' age, Tac dose) on MPA, fMPA and MPAG pharmacokinetic parameters. We found one study, concerning patients receiving EC-MPS and CsA, where neither MPA nor MPAG pharmacokinetics correlated with WBC and PLT counts or with Hb and albumin concentrations (Stracke et al. [@CR27]). In our study, no significant correlations, except for lower Hb concentrations in patients with higher MPA *C*~0~ and fMPA *C*~0~, were observed. Nevertheless, these correlations indicate the necessity of MPA *C*~0~ monitoring during EC-MPS and Tac treatment as too high MPA *C*~0~ may contribute to anemia onset in these patients.

Conclusion {#Sec12}
==========

The significant correlations between MPA *C*~3~ as well as MPA *C*~4~ and MPA AUC~0--4~ and MPA AUC~0--12~ may be of importance in further studies including larger number of patients in regard to establishing LSS. Similarly as for MMF therapy, in EC-MPS treated patients MPAG concentration is related to renal function as MPAG pharmacokinetics were higher in patients with renal impairment. In patients treated with EC-MPS and Tac, monitoring MPA *C*~0~ may be important, as too high MPA *C*~0~ may contribute to anemia onset. However, it should be emphasized that there are some limitations in this study, e.g. the lack of a control group, the cross-sectional design and the small number of patients. This work may serve as a starting point for further and multicenter studies.
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